



## Hematological Malignancies

Guest Editor:

**Prof. Dr. Maria Moschovi**

Hematology/Oncology Unit, 1st  
Department of Pediatrics, "Agia  
Sophia" Children's Hospital,  
School of Medicine, National and  
Kapodistrian University of  
Athens, 10679 Athens, Greece

Deadline for manuscript  
submissions:

**closed (31 May 2021)**

### Message from the Guest Editor

Chronic myelogenous leukemia is the first hematological malignancy for which a drug was devised against the molecular hallmark of the disease. Juvenile myelomonocytic leukemia constitutes an archetype of genetic predisposition to hematological malignancy with specific correlations of genotype–phenotype. Genetic predisposition to myeloid neoplasms provides an additional basis of hematological malignancy classification. Histiocytic syndromes are caused by ‘druggable’ mutations in the RAS-MAPK pathway. Genetic alterations in key molecules of lymphopoiesis are the basis of prognostic stratification in acute lymphoblastic leukemia. Rare subtypes of lymphoma are also carried by specific molecular abnormalities such as anaplastic lymphoma and ALK mutations.

The aim of this issue is to offer an overview of molecular targets in pediatric hematological malignancies and their therapeutic counterpart. Several neoplasms should be covered, and we invite authors to choose topics well beyond acute leukemia.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Maurizio Battino

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

## Contact Us

---

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI